Telix completes Japan Phase 3 enrollment for Illuccix
July 17, 2026 | 10:23
Telix Pharmaceuticals, dual-listed on ASX and Nasdaq, completed patient enrollment in its pivotal Phase 3 registration study of TLX591-Px, branded Illuccix, for prostate cancer imaging in Japan.
Mobile Version